P
eritonitis is one of the major complications of peritoneal dialysis (PD). The majority of PD-related peritonitis cases are caused by pathogenic bacteria, with only a small number of cases being caused by fungi, primarily Candida species, and Mycobacterium species. Currently, the novel diagnostic techniques that have been explored for the early diagnosis of PD-related peritonitis are primarily limited to the identification of bacterial pathogens (1) (2) (3) . In this study, we aimed to determine the feasibility of and potential application of the BAC detection assay (Ibis Biosciences) in multilocus PCR coupled with electrospray ionization mass spectrometry (PCR/ESI-MS) (PLEX-ID; Abbott Laboratories, IL) for the rapid detection of, identification of, and information on drug resistance of bacteria and Candida species in PD effluent from patients with PD-related peritonitis.
Nineteen patients who had 21 episodes of PD-related peritonitis, including 19 episodes from 17 patients at National Cheng Kung University Hospital (NCKUH) (2 patients experienced second episodes) and 2 episodes at Chi-Mei Medical Center (CMMC) (patients 12 and 17), were enrolled after informed consent was obtained between July 2012 and April 2013 ( Table 1) . The diagnosis of PD-related peritonitis followed the diagnostic criteria recommended by the International Society for Peritoneal Dialysis (3). Three samples of PD effluent from patients without peritonitis were used as control samples. For pathogen detection, the PD effluent, obtained prior to antimicrobial treatments, was subjected to both traditional culture and PCR/ESI-MS analyses. For culture analyses, 20 ml of centrifugation sediment from 50-ml and 20-ml samples of PD effluent obtained from patients at NCKUH and CMMC, respectively, was inoculated into Bactec aerobic/anaerobic blood culture bottles (10 ml/bottle) and Myco/F lytic bottles where indicated and cultivated using the Bactec 9240 blood culture system (BD Diagnostics). Microorganisms were identified based on the standard phenotypic tests used in clinical microbiology laboratories (4), and antimicrobial susceptibility was determined using the disk diffusion method (5) . For PCR/ESI-MS analyses, 50 ml of PD effluent was centrifuged at 14,000 rpm for 10 min. DNA was then extracted and purified from the resulting cell pellets using the UMD-Universal extraction kit according to the protocol supplied by the manufacturer (Molzym, Bremen, Germany), and elutes were stored at Ϫ20°C until testing. The DNA extraction kit includes protocols for the lysis of human cells, degradation of the human DNA by a DNase, and lysis of the cell walls of any bacteria and yeasts by treatment with BugLysis and ␤-mercaptoethanol. On PCR/ESI-MS analyses, extracted DNA was added to a BAC detection assay plate and amplified and analyzed using PCR/ESI-MS. The BAC detection assay plate contains a set of 18 different primer pairs for the detection and identification of bacterial and Candida species and the mecA, vanA, vanB, and Klebsiella pneumoniae carbapenemase antibiotic resistance genes (6) . The procedures for PCR/ESI-MS analysis followed the manufacturer's instructions as previously described, with a test turnaround time within 6 to 8 h (6, 7). Organism identification was based on the total mass and base compositions of the PCR amplicons compared to those in the molecular signature database established by the PLEX-ID manufacturer. The genome level, indicating the amount of amplified DNA present in the sample reported as genome equivalents per well, was calculated as previously described (Table 1) (8) . The limits of detection determined by PCR/ESI-MS were 10 2 CFU/ml for Staphylococcus aureus ATCC25923 and Escherichia coli ATCC25922 and 10 1 CFU/ml for Candida albicans ATCC14053, using three independent 10-fold dilution panels (10 1 to 10 3 CFU/ml) of 3-ml whole-blood samples. Of the 21 episodes of PD-related peritonitis, cultures and PCR/ ESI-MS identified microorganisms in 16 (76%) and 18 (86%) samples, respectively, and overall, 19 (90%) samples were positive either by culture or PCR/ESI-MS (Table 1) . Notably, PCR/ESI-MS failed to identify a second pathogen in 2 samples (patients 12 and 18). No pathogen was detected by either method in 3 control samples. Among the 15 organisms identified by both methods, PCR/ESI-MS and culture reached an agreement of 100% (15/15) at the genus level, and among 8 isolates with species-level identification by the conventional phenotypic method, an agreement of 87.5% (7/8) was reached at the species level. 16S rRNA gene sequence analyses of the PD effluent samples further confirmed the PCR/ESI-MS results at the species level in 6 isolates without species-level identification by the conventional phenotypic method and in the cases of Mycobacterium tuberculosis and Legionella pneumophila (Table 1) . Target-specific PCR analyses confirmed the PCR/ESI-MS result of Escherichia coli in patient 12, whereas no PCR product was found for detection of Klebsiella pneumoniae in patient 12 and for Streptococcus salivarius in patient 18. In patient 3, the pathological examination of the peritoneal biopsy specimen in the second episode of peritonitis showed suppurative granulomatous inflammation composed of multinucleated giant cells and visible acid-fast bacilli, suggestive of M. tuberculosis infection, and anti-tuberculosis therapy was initiated. In retrospect, PCR/ ESI-MS analysis of the PD effluent obtained 80 days earlier in an (16) . f PD effluent was analyzed by target-specific PCR. The primers for target-specific PCR included UAL1936b/UAL2105b for E. coli, K16SF/K16SR for K. pneumoniae, and MKK-F/ MKK-R and 13BF/6R for S. salivarius (12) (13) (14) (15) . g Two separate episodes occurred 5 months apart. h Isolate for which genus identification was further confirmed using the Rapid ID 32A system (bioMérieux, Marcy-l'Etoile, France). i Isolates for which species identification was further confirmed using the Vitek system (bioMérieux Vitek, Hazelwood, MO). j Two separate episodes occurred 1 month apart. k GPB, Gram-positive bacilli. l The 16S rRNA gene sequences from both PD effluent and the isolate were only 98.3% (1401/1425) identical to that of S. warneri (GenBank accession no. NR_025922).
episode of cloudy PD effluent (dialysate leukocyte count, 233/l; neutrophils, 33%) also detected M. tuberculosis. Mycobacterial cultures of the PD effluent samples from both occasions were negative. Although patient 7 recovered with piperacillin-tazobactam treatment, the clinical significance of the detection of the nucleic acid of L. pneumophila was not clear. Antimicrobial susceptibility testing of the culture isolates did not demonstrate carbapenem resistance in Gram-negative bacilli, vancomycin resistance in Gram-positive cocci, or oxacillin resistance in staphylococci, consistent with the finding that antimicrobial resistance genes were not detected by PCR/ESI-MS in any of the samples. In this study, PCR/ESI-MS demonstrated its capability to rapidly identify a broad spectrum of pathogens, including uncommonly encountered organisms such as Mycobacterium and Candida species, in a single examination without foreknowledge of the microorganisms potentially present. This is of particular importance for patients with tuberculous peritonitis because the presentation of tuberculous peritonitis in this population might be insidious, making the diagnosis challenging. The potential of PCR/ESI-MS for the early diagnosis of tuberculous peritonitis is promising because earlier antituberculosis treatment aids the preservation of the peritoneal membrane ultrafiltration capacity (9) . Furthermore, our study and previous reports indicate that at the genus and species levels, PCR/ESI-MS identification can achieve high degrees of concordance with standard techniques used in clinical microbiology laboratories (6, 7) . In addition, the presence of antibiotic resistance genes can be examined. Rapid and accurate identification of pathogens and their associated antibiotic resistance genes directly from PD effluent might guide clinicians toward a more rapid and earlier shift from the use of broad-spectrum empirical antimicrobials to targeted antibiotics.
However, PCR/ESI-MS does have its limitations. Although PCR/ESI-MS has the ability to resolve mixtures, the technology failed to detect mixed pathogens in two of our samples. Additionally, in a previous report, it had a relatively high false-negative error rate of 24% in detecting mixtures in blood culture bottles, most likely due to preferential amplification, as the primers were quickly saturated with DNA from the most abundant organism, leaving microorganisms present in lower titers undetected (6) . Because polymicrobial peritonitis represented approximately 10% of all PD-related peritonitis episodes (10) , the possibility of a false-negative PCR/ESI-MS result should be considered. Second, PCR/ESI-MS cannot provide detailed antimicrobial susceptibility information for the causative organisms, unlike culturing, which was used to guide postempirical antibiotic treatment. Therefore, although sensitive and rapid for pathogen detection, PCR/ESI-MS cannot replace, but may complement, culture methods in the diagnosis of PD-related peritonitis.
In conclusion, this study supports the use of PCR/ESI-MS as a potential tool for rapid and broad-range pathogen detection in PD-related peritonitis.
